Information TechnologyIT - SoftwareComputers - Software & Consulting

Covidh Technologies Ltd

Showing the latest 10 filings. Sign in to filter or browse the full history.
10 of 60 filings·Updated 13 Oct 2026
Showing 10 of 60 filings.
13 Oct 20261 filing
Company UpdateCertificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

No physical certificates received for dematerialisation; no demat requests in period

Dematerialisation status

  • No physical share certificates were received for dematerialisation during the quarter ended 30 September 2026.
  • No dematerialisation/rematerialisation requests were received during the period.
Filed 18:40View Source
30 Sept 20261 filing
AGM/EGMAGM

iSERA Lifesciences AGM 2026 approves financials and director reappointment

AGM Details

  • AGM held 29 September 2026 at 3:00 PM; physical meeting with VC/OAVM attendance facility.

Resolutions Proposed

  • Adopt financial statements for year ended 31 March 2026, including balance sheet, P&L, and reports.
  • Ordinary resolution for reappointment of director by rotation (Jitendra Prabhakar Nene).

Voting Result

  • Both ordinary resolutions passed by requisite majority; total votes in favour 781,837.

Director Changes

  • Director Jitendra Prabhakar Nene reappointed by rotation.
Filed 17:58View Source
29 Sept 20261 filing
AGM/EGMAGM

iSERA Lifesciences holds 34th AGM via video conference; ordinary resolutions on accounts and director re-appointment approved.

AGM Details

  • AGM held on 29 September 2026 at 3:00 PM via video conference.
  • Deemed to be held at the registered office address.
  • Attendance: 47 members attended.
  • Remote e-voting window: 26-28 Sept 2026; voting also during meeting.
  • Scrutinizer: Anuj Gupta, Company Secretary in practice.

Resolutions & Results

  • Ordinary Business: adoption of Audited Financial Statements for year ended 31 March 2026.
  • Ordinary Business: re-appointment of Mr. Jitendra Prabhakar Nene as director liable to retire by rotation.
  • Outcomes: both resolutions passed by Ordinary Resolution.
  • Voting mode: remote e-voting plus voting at meeting.
Filed 16:35View Source
28 Sept 20261 filing
Insider Trading / SASTClosure of Trading Window

iSERA Lifesciences Ltd – Closure of Trading Window

iSERA Lifesciences Ltd – Closure of Trading Window

Filed 16:28View Source
7 Sept 20261 filing
Company UpdateNewspaper Publication

We hereby submit the copy of Newspaper Publication of Public Notice regarding 34th Annual General Meeting ('AGM') of the Company , scheduled to be held on Tuesday, September 29, 2026, at ....

No brief for this announcement.Newspaper publications aren’t summarised. View the original using the link below
Filed 14:18View Source
2 Sept 20261 filing
Company UpdateNewspaper Publication

iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited) has filed with the exchange copy of newspaper publication.

No brief for this announcement.Newspaper publications aren’t summarised. View the original using the link below
Filed 12:51View Source
7 Aug 20262 filings
ResultFinancial Results

iSERA Lifesciences: Q1 FY27 revenue ₹121.95 cr, loss ₹0.34 cr; FY26 revenue ₹142.52 cr, PAT ₹25.94 cr

Financial Highlights

  • Unaudited Q1 FY27 total revenue ₹12,195 lakh; revenue from operations ₹11,618 lakh; other income ₹577 lakh.
  • Net loss after tax ₹33.52 lakh; basic/diluted EPS ₹-1.60 for Q1.
  • FY26: total revenue ₹14,252 lakh; PAT ₹2,594 lakh; EPS basic ₹0.74; diluted ₹0.78.
  • Board approved results on June 7, 2026; filing to exchanges on August 7, 2026.
  • Single segment IT/ITES, no reportable segments per Ind AS-108.
  • Paid-up equity share capital ₹840.90 lakh; reserves (excluding revaluation reserve) ₹-36.19 lakh.
Filed 14:49View Source
Board MeetingOutcome of Board Meeting

iSERA Lifesciences approves unaudited standalone Q1 2026-27 results with Limited Review report

Financial results approved

  • Unaudited standalone results for quarter ended 30 June 2026 approved.

Audit report

  • Independent Auditor's Limited Review Report on unaudited standalone results enclosed.

Auditor details

  • Auditor: GMKS & Co Chartered Accountants.
Filed 14:39View Source
14 Jul 20261 filing
Company UpdateCertificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Certificate confirms Reg 74(5) compliance for dematerialisation activities

Certificate details

  • Compliance with Reg 74(5) confirmed for the period.
  • Relates to physical share certificates received for dematerialisation of equity shares.
Filed 12:34View Source
29 Jun 20261 filing
AGM/EGMPostal Ballot

iSERA Lifesciences approves two amendments to Explanatory Statement via reopened postal ballot

Purpose

  • Re-opened postal ballot to amend Explanatory Statement to Item 7 of April 21 notice.

Resolutions

  • Resolution 1 (Special): Corrects typographical error in Dhairyasheel Yadav share allotment.
  • Resolution 2 (Special): Amend post-issue holding percentage and change in control disclosures.

Outcome

  • Both resolutions approved by requisite majority via reopened e-voting; 100% of polled votes in favour.

Material impact

  • Amendments are disclosures; no change to underlying preferential issue terms.

Notes

  • Promoter group identified as interested party; no explicit abstention stated.
Filed 19:07View Source
Showing 10 of 60 filings